The question that decides your pathway

The answer to 'do I need ChondroFiller or something for osteoarthritis?' depends less on symptoms than on the shape of the damage inside the knee. Pain, swelling, and stiffness can look identical whether the problem is a discrete patch of cartilage loss or degeneration spread across a whole compartment — which is why a diagnosis based on symptoms alone cannot reliably separate the two.

The distinction that matters is anatomical. A focal chondral defect is a contained lesion in a joint that is otherwise structurally sound. Early osteoarthritis, by contrast, involves cartilage change spread across a compartment alongside alterations in the underlying bone and joint lining. ChondroFiller is indicated for the focal pathway; early OA calls for a different approach. Imaging and specialist assessment — not symptoms — are what determine which applies, and in some knees, MRI reveals both patterns present at once.

This is, in other words, a pathway-selection question rather than a product choice, and the answer rests on what a scan and a clinical assessment actually show.

What a focal cartilage defect looks like

Clinicians use the term 'focal and contained' to describe a defect that has clear edges — a discrete crater or patch of cartilage loss that does not spill across the wider joint surface. The ICRS grading scale communicates how deep that loss goes: Grade 2 means less than half the cartilage thickness is involved; Grade 3 means more than half, with subdivisions tracking whether damage has reached the calcified layer just above bone; Grade 4 means full-thickness loss down to the subchondral bone itself. ChondroFiller's injectable collagen scaffold is designed to address defects across this depth range, from partial to full thickness.

The causes are often traceable in the patient's own history. A twisting sports injury, a direct blow to the knee, osteochondral dissecans (OCD) — a condition in which a segment of bone and cartilage loses its blood supply and may separate — or years of repetitive loading on a joint with abnormal alignment are among the most common origins. Many patients recall a specific event or a progressive ache that began after high-impact activity.

Two factors shape how a specialist evaluates suitability. First, the quality of the surrounding cartilage: a well-defined lesion sitting within healthy tissue is a different clinical picture from one surrounded by softening or thinning cartilage, which may suggest early degenerative change beginning to spread. Second, defect size: lesions over approximately 1 cm carry a recognised risk of progression to osteoarthritis if left untreated, which is why early intervention carries a disease-modifying rationale rather than being purely symptomatic management.

What early osteoarthritis looks like

Early OA is not a single lesion but a progressive, compartment-wide process — the earliest phase in which cartilage degeneration and subchondral bone change begin to spread rather than stay contained. Clinically, this tends to manifest as activity-related pain that eases with rest, painless crepitus, joint-line tenderness, and early osteophyte formation; radiological joint-space narrowing, by contrast, is a later sign that may be absent at this stage.

The 2014 Tokyo First International Early Knee OA Workshop established the first formal consensus classification for the condition, and OARSI grading captures both depth of cartilage loss (grade) and its spatial spread across the compartment (stage) — the latter being what structurally separates early OA from a focal defect.

Meniscal damage adds a further dimension. Research from the Framingham study and a 2016 paper by Verdonk et al. in Knee Surgery, Sports Traumatology, Arthroscopy established that meniscal degeneration should be understood as part of early OA rather than an isolated finding — reinforcing that early OA is a whole-joint process.

Because the degeneration is diffuse rather than contained, MRI is the practical differentiator: subchondral oedema, osteophyte size, and the extent of cartilage change across the compartment together help a specialist judge whether the picture is focal, early OA, or a mixture of both — and it is that distinction which determines how treatment planning proceeds.

How ChondroFiller works in the focal-defect pathway

Placed as an ultrasound-guided injection in an outpatient setting, ChondroFiller delivers a sterile acellular type I collagen scaffold directly into the cartilage defect — no general anaesthetic and no theatre admission are involved in this pathway. The scaffold acts as a three-dimensional framework inside the lesion: over the following six to twelve months, the patient's own progenitor cells — drawn from the surrounding synovial fluid and from the subchondral bone beneath the defect — migrate into the matrix and begin laying down new cartilage tissue. This process is sometimes described as acellular matrix-induced chondrogenesis; in plain terms, the injection gives the body a structure to build on, rather than introducing cells from an external source.

Published cohort data show that in focal knee defects, IKDC knee scores have improved by around 30 points — on a 100-point scale where higher scores represent better function and lower pain, a shift of that size typically corresponds to a meaningful change in day-to-day activity and the ability to return to lower-impact sport. MOCART MRI scores, which grade how completely a defect has been filled with repair tissue on imaging (also out of 100), have reached 70 to 87 in reported series, indicating substantial to near-complete defect fill at the site of the original lesion. More than 19,000 cases have been carried out globally across the knee, hip, ankle, and smaller joints.

These results come from observational cohort series rather than randomised trials, so they reflect outcomes in real-world treated patients rather than a controlled experimental comparison. That distinction matters less for ruling ChondroFiller in or out than for calibrating expectations: how closely an individual's outcome might resemble published figures depends on defect depth, the quality of the surrounding cartilage, and overall joint health — all factors that a specialist assessment is designed to weigh before any decision is made.

When Arthrosamid fits — and when both treatments apply

Some MRI reports present a mixed picture: a discrete focal lesion sitting within a joint that also shows early OA changes — osteophyte formation, subchondral signal alteration, or diffuse cartilage thinning across the compartment. That combination is where Arthrosamid becomes relevant, because it addresses a different anatomical structure entirely.

Arthrosamid is a polyacrylamide hydrogel that integrates into the synovial lining of the knee rather than filling a cartilage defect. Its role is mechanical: it cushions the joint from within the synovial membrane, providing longer-term support for an OA-affected compartment. It does not recruit cells, lay down matrix, or aim to restore a cartilage surface — and ChondroFiller, by the same logic, does not cushion the synovial lining. Each product operates through a distinct mechanism on a distinct tissue; combining them in a single appointment is a way of addressing both problems at once, not a way of doubling the dose of one treatment.

Registry cohort data supporting Arthrosamid in knee OA extends to two to three years — a different evidence profile from the focal-defect cohort data that underpins ChondroFiller, which reflects the different populations each product is designed for.

For patients whose scan shows only early OA without a contained focal lesion, ChondroFiller's indication does not apply — the scaffold needs a defined defect to fill. In those cases, honest pathway-matching means directing the assessment towards the synovial or OA side of the treatment ladder. A specialist assessment can determine whether the picture is focal, diffuse, or mixed, and whether one or both options merit discussion.

Questions to ask at a specialist assessment

Four questions are worth putting directly to a specialist.

Does the imaging show a focal, contained defect or signs of diffuse degeneration? This is the core pathway question — every other decision follows from it.

What is the ICRS grade of the lesion, and what does the surrounding cartilage look like? Defect depth and the quality of the surrounding tissue both affect suitability and what outcomes are realistic.

What published outcome data applies to my joint, defect size, and age group? Most available cohort evidence is knee-focused; a specialist can indicate how directly it extends to hip, ankle, or smaller joints.

If the scan shows both focal damage and OA change, have both ChondroFiller and Arthrosamid been considered — and why, or why not? This tests whether the assessment has genuinely engaged with a mixed picture rather than defaulting to one pathway.

Search MSK lists specialists across the UK who offer ChondroFiller assessment and ultrasound-guided injection — filter by region and specialty to find one suited to your situation.

The more important step before any treatment decision, however, is confirming whether a focal, contained defect is present at all. Directing a regenerative scaffold at diffuse OA, or a synovial hydrogel where a contained defect needs filling, addresses the wrong structure by the wrong mechanism. The questions above are a practical way of checking, before any commitment, that the assessment has made that distinction clearly.